CAPTRUST Financial Advisors
ALDX icon

CAPTRUST Financial Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.5K Buy
52,947
+952
+2% +$4.17K ﹤0.01% 2827
2025
Q4 		$269K Sell
51,995
-999
-2% -$5.13K ﹤0.01% 2327
2025
Q3 		$277K Buy
52,994
+1,502
+3% +$7.83K ﹤0.01% 2225
2025
Q2 		$197K Buy
51,492
+4,297
+9% +$11.1K ﹤0.01% 2312
2025
Q1 		$271K Buy
47,195
+26,500
+128% +$157K ﹤0.01% 1995
2024
Q4 		$103K Buy
20,695
+1,434
+7% +$7.36K ﹤0.01% 2202
2024
Q3 		$104K Buy
19,261
+9,087
+89% +$43.3K ﹤0.01% 2199
2024
Q2 		$33.7K Buy
10,174
+135
+1% +$529 ﹤0.01% 2164
2024
Q1 		$32.8K Sell
10,039
-9,453
-48% -$31.1K ﹤0.01% 2102
2023
Q4 		$68.4K Sell
19,492
-10,936
-36% -$33.7K ﹤0.01% 2561
2023
Q3 		$203K Buy
30,428
+15,339
+102% +$114K ﹤0.01% 2279
2023
Q2 		$127K Buy
+15,089
New +$149K ﹤0.01% 2348
2022
Q3 		– Sell
-1,089
Closed -$4K – 2119
2022
Q2 		$4K Sell
1,089
-181
-14% -$622 ﹤0.01% 4157
2022
Q1 		$6K Buy
1,270
+770
+154% +$3.07K ﹤0.01% 4045
2021
Q4 		$2K Buy
+500
New +$3.81K ﹤0.01% 4385

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAPTRUST Financial Advisors's ALDX Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Aldeyra Therapeutics (ALDX) stake by 1.8% in Q1 2026, buying an estimated $4.17K and bringing the position to 52,947 shares worth $89.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2827.

CAPTRUST Financial Advisors first reported a position in ALDX in Q4 2021 and has held it in 15 quarters since. The position peaked at $277K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • CAPTRUST Financial Advisors held 52,947 shares of Aldeyra Therapeutics worth $89.5K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 952 Aldeyra Therapeutics shares in Q1 2026, an estimated $4.17K.
  • Aldeyra Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2827 holding.
  • CAPTRUST Financial Advisors first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • CAPTRUST Financial Advisors's Aldeyra Therapeutics position peaked at $277K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.